Dietary and donepezil modulation of mTOR signaling and neuroinflammation in the brain

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 2, 2016, Pages 274-283

  Dasuri, Kalavathi ^a,b   Zhang, Le ^a,c   Kim, Sun O K Fernandez ^a   Bruce Keller, Annadora J ^a   Keller, Jeffrey N ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Aging; Brain; Donepezil; High fat diet; MTOR pathway; Neurodegenerative disorders; Neuroinflammation; Obesity

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID DIET; MALE; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84951177051     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.11.002     Document Type: Article

References (57)

1. Cancello R., Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 2006, 113:1141-1147.
2. Lee C.H., Woo Y.C., Wang Y., Yeung C.Y., Xu A., Lam K.S. Obesity, adipokines and cancer: an update. Clin. Endocrinol. 2015, 83:147-156.
3. Rahmouni K., Correia M.L., Haynes W.G., Mark A.L. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005, 45:9-14.
4. Walker G.E., Marzullo P., Ricotti R., Bona G., Prodam F. The pathophysiology of abdominal adipose tissue depots in health and disease. Horm. Mol. Biol. Clin. Invest. 2014, 19:57-74.
5. Cai D., Liu T. Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. Aging 2012, 4:98-115.
6. De Souza C.T., Araujo E.P., Bordin S., Ashimine R., Zollner R.L., Boschero A.C., Saad M.J., Velloso L.A. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 2005, 146:4192-4199.
7. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
8. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29:415-445.
9. Beydoun M.A., Beydoun H.A., Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev. 2008, 9:204-218.
10. Freeman L.R., Zhang L., Nair A., Dasuri K., Francis J., Fernandez-Kim S.O., Bruce-Keller A.J., Keller J.N. Obesity increases cerebrocortical reactive oxygen species and impairs brain function. Free Radic. Biol. Med. 2013, 56:226-233.
11. Pepping J.K., Freeman L.R., Gupta S., Keller J.N., Bruce-Keller A.J. NOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2013, 304.
12. Thaler J.P., Yi C.X., Schur E.A., Guyenet S.J., Hwang B.H., Dietrich M.O., Zhao X., Sarruf D.A., Izgur V., Maravilla K.R., Nguyen H.T., Fischer J.D., Matsen M.E., Wisse B.E., Morton G.J., Horvath T.L., Baskin D.G., Tschop M.H., Schwartz M.W. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 2012, 122:153-162.
13. Davidson T.L., Hargrave S.L., Swithers S.E., Sample C.H., Fu X., Kinzig K.P., Zheng W. Inter-relationships among diet, obesity and hippocampal-dependent cognitive function. Neuroscience 2013, 253:110-122.
14. Freeman L.R., Haley-Zitlin V., Rosenberger D.S., Granholm A.C. Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. Nutr. Neurosci. 2014, 17:241-251.
15. Freeman L.R., Granholm A.C. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. J. Cereb. Blood Flow Metab. 2012, 32:643-653.
16. Stranahan A.M., Norman E.D., Lee K., Cutler R.G., Telljohann R.S., Egan J.M., Mattson M.P. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008, 18:1085-1088.
17. Graber T.E., McCamphill P.K., Sossin W.S. A recollection of mTOR signaling in learning and memory. Learn. Mem. 2013, 20:518-530.
18. Laplante M., Sabatini D.M. MTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
19. Laplante M., Sabatini D.M. MTOR signaling in growth control and disease. Cell 2012, 149:274-293.
20. Saha A.K., Xu X.J., Balon T.W., Brandon A., Kraegen E.W., Ruderman N.B. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?. Cell Cycle 2011, 10:3447-3451.
21. An W.L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.G., Winblad B., Pei J.J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 2003, 163:591-607.
22. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
23. Hoeffer C.A., Klann E. MTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010, 33:67-75.
24. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005, 272:4211-4220.
25. Orr M.E., Salinas A., Buffenstein R., Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol. Aging 2014, 35:1233-1242.
26. Tramutola A., Triplett J.C., Di Domenico F., Niedowicz D.M., Murphy M.P., Coccia R., Perluigi M., Butterfield D.A. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J. Neurochem. 2015, 133:739-749.
27. Perluigi M., Di Domenico F., Butterfield D.A. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol. Dis. 2015.
28. Tang Z., Ioja E., Bereczki E., Hultenby K., Li C., Guan Z., Winblad B., Pei J.J. MTor mediates tau localization and secretion: implication for Alzheimer's disease. Biochim. Biophys. Acta 2015, 1853:1646-1657.
29. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., Donepezil M.S.I.G. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57:613-620.
30. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 920:321-327.
31. Kim H.G., Moon M., Choi J.G., Park G., Kim A.J., Hur J., Lee K.T., Oh M.S. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014, 40:23-32.
32. Saxena G., Singh S.P., Agrawal R., Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur. J. Pharmacol. 2008, 581:283-289.
33. Meunier J., Ieni J., Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol. 2006, 149:998-1012.
34. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006, 51:474-486.
35. Wilkinson D.G., Francis P.T., Schwam E., Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004, 21:453-478.
36. Zhang L., Dasuri K., Fernandez-Kim S.O., Bruce-Keller A.J., Freeman L.R., Pepping J.K., Beckett T.L., Murphy M.P., Keller J.N. Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice. Biochim. Biophys. Acta 2013, 1832:1456-1462.
37. Gupta S., Knight A.G., Losso B.Y., Ingram D.K., Keller J.N., Bruce-Keller A.J. Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. Antivir. Res. 2012, 95:19-29.
38. Bruce-Keller A.J., Gupta S., Knight A.G., Beckett T.L., McMullen J.M., Davis P.R., Murphy M.P., Van Eldik L.J., Clair D.S., Keller J.N. Cognitive impairment in humanized APPxPS1 mice is linked to Abeta(1-42) and NOX activation. Neurobiol. Dis. 2011, 44:317-326.
39. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
40. Puig K.L., Floden A.M., Adhikari R., Golovko M.Y., Combs C.K. Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS One 2012, 7.
41. Buckman L.B., Thompson M.M., Moreno H.N., Ellacott K.L. Regional astrogliosis in the mouse hypothalamus in response to obesity. J. Comp. Neurol. 2013, 521:1322-1333.
42. Bartolini M., Bertucci C., Cavrini V., Andrisano V. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65:407-416.
43. Valdearcos M., Robblee M.M., Benjamin D.I., Nomura D.K., Xu A.W., Koliwad S.K. Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function. Cell Rep. 2014, 9:2124-2138.
44. Strissel K.J., Stancheva Z., Miyoshi H., Perfield J.W., DeFuria J., Jick Z., Greenberg A.S., Obin M.S. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
45. Chiang G.G., Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 2005, 280:25485-25490.
46. Tremblay F., Brule S., Hee Um S., Li Y., Masuda K., Roden M., Sun X.J., Krebs M., Polakiewicz R.D., Thomas G., Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14056-14061.
47. Dello Russo C., Lisi L., Tringali G., Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem. Pharmacol. 2009, 78:1242-1251.
48. Park J., Zhang J., Qiu J., Zhu X., Degterev A., Lo E.H., Whalen M.J. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J. Cereb. Blood Flow Metab. 2012, 32:330-340.
49. Catalan V., Gomez-Ambrosi J., Rodriguez A., Ramirez B., Andrada P., Rotellar F., Valenti V., Moncada R., Marti P., Silva C., Salvador J., Fruhbeck G. Expression of S6K1 in human visceral adipose tissue is upregulated in obesity and related to insulin resistance and inflammation. Acta Diabetol. 2015, 52:257-266.
50. Stemmer K., Perez-Tilve D., Ananthakrishnan G., Bort A., Seeley R.J., Tschop M.H., Dietrich D.R., Pfluger P.T. High-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. Dis. Model. Mech. 2012, 5:627-635.
51. Weichhart T., Haidinger M., Katholnig K., Kopecky C., Poglitsch M., Lassnig C., Rosner M., Zlabinger G.J., Hengstschlager M., Muller M., Horl W.H., Saemann M.D. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011, 117:4273-4283.
52. Dong H., Yuede C.M., Coughlan C.A., Murphy K.M., Csernansky J.G. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res. 2009, 1303:169-178.
53. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H., Akaike A. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 2003, 306:772-777.
54. Yoshiyama Y., Kojima A., Ishikawa C., Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J. Alzheimers Dis. 2010, 22:295-306.
55. Gkogkas C.G., Sonenberg N. Translational control and autism-like behaviors. Cell. Logist. 2013, 3.
56. Weatherill D.B., Dyer J., Sossin W.S. Ribosomal protein S6 kinase is a critical downstream effector of the target of rapamycin complex 1 for long-term facilitation in aplysia. J. Biol. Chem. 2010, 285:12255-12267.
57. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. MTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.